$0.01
(Market cap
$21 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
11.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.4 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
-1.9
-
Debt to Equity
-4.1
-
Book Value
$--
-
EPS
$-0.3
-
Face value
--
-
Shares outstanding
62,842,748
10 Years Aggregate
CFO
$-125.97 Mln
EBITDA
$-160.18 Mln
Net Profit
$-168.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cytosorbents Crp (CTSO)
| -45.3 | -3.1 | -28.7 | -62.9 | -48.6 | -48.4 | -23.4 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cytosorbents Crp (CTSO)
| -29.8 | -17.9 | -28.4 | -63.0 | -47.4 | 107.0 | -52.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cytosorbents Crp (CTSO)
|
0.3 | 21.1 | 37.2 | -18.2 | -41.6 | -- | -- | 11.4 |
| 60.9 | 8,018.1 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.2 | |
| 14.2 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 56.0 | 8,696.7 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 176.8 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.9 | 6,577.5 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.1 | 5.0 | |
| 90.5 | 5,403.2 | 1,579.2 | 145.6 | 14.3 | 8.9 | 37.2 | 3.2 | |
| 322.7 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 168.3 | 9,947.9 | 785.1 | 41.5 | 9.9 | 2 | 251.8 | 4.9 |
Shareholding Pattern
View DetailsAbout Cytosorbents Crp (CTSO)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an... extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. Read more
-
CEO & Director
Dr. Phillip P. Chan M.D., Ph.D.
-
CEO & Director
Dr. Phillip P. Chan M.D., Ph.D.
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cytosorbents Crp (CTSO)
What is the current share price of Cytosorbents Crp (CTSO) Today?
The share price of Cytosorbents Crp (CTSO) is $0.35 (NASDAQ) as of 01-Sep-2026 15:34 EDT. Cytosorbents Crp (CTSO) has given a return of -48.62% in the last 3 years.
What is the current PB & PE ratio of Cytosorbents Crp (CTSO)?
Since, TTM earnings of Cytosorbents Crp (CTSO) is negative, P/E ratio is not available.
The P/B ratio of Cytosorbents Crp (CTSO) is 11.43 times as on 28-Aug-2026, a 202 premium to its peers’ median range of 3.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.90 |
6.80 |
2024 |
-2.40 |
4.48 |
2023 |
-1.69 |
2.13 |
2022 |
-2.05 |
1.91 |
2021 |
-7.42 |
2.91 |
What is the 52 Week High and Low of Cytosorbents Crp (CTSO)?
The 52-week high and low of Cytosorbents Crp (CTSO) are Rs 1.04 and Rs 0.30 as of 02-Sep-2026.
What is the market cap of Cytosorbents Crp (CTSO)?
Cytosorbents Crp (CTSO) has a market capitalisation of $ 21 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cytosorbents Crp (CTSO)?
Before investing in Cytosorbents Crp (CTSO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.